Oral Wegovy (Semaglutide 25mg Tablet) Wins FDA Approval. 16.6% Weight Loss at 64 Weeks Plus 20% Cardiovascular Event Reduction
The barrier to obesity treatment just dropped again. Novo Nordisk’s oral Wegovy (semaglutide 25mg tablet) received FDA approval in January 2026 as the first oral GLP-1 with both obesity and cardiovascular indications. US launch began in early 2026. Until now, every GLP-1 (Wegovy, Ozempic, Mounjaro, Zepbound) was injectable. Weekly self-injection has been the entry barrier for hesitant patients. The oral option dismantles that barrier.
The pivotal data come from OASIS 4 phase 3. At 64 weeks, oral semaglutide 25mg achieved mean 16.6% weight loss (full adherence basis), versus 2.7% on placebo. One-third of adherent participants achieved 20% or greater weight loss; under 3% on placebo. Efficacy lands close to injectable Wegovy (2.4mg weekly), now translatable into a daily pill.
Cardiovascular efficacy was established in SELECT. 17,604 patients (obesity/overweight without diabetes plus pre-existing cardiovascular disease) showed a 20% reduction in major adverse cardiovascular events (myocardial infarction, stroke, cardiovascular death). Mean weight loss -10.2%, waist circumference -7.7cm, sustained over 4 years. Weight loss is cumulative and durable, not transient.
The clinical relevance for women is layered:
-
High injection refusal rate: An estimated 30–40% of Korean GLP-1 prescriptions discontinue after the first 1~2 injections. Needle aversion and self-injection difficulty are key drivers. Oral pills nearly eliminate this barrier.
-
Post-menopausal weight gain: Estrogen decline drops basal metabolism by 5–10%, accelerates visceral adiposity. Annual 1~2kg gain is the typical pattern. Diet and exercise alone become insufficient — pharmacological assistance gains weight.
-
PCOS insulin resistance + body weight: 60–70% of PCOS women have overweight/obesity. Oral GLP-1 acts on insulin sensitivity + body weight + androgen signaling simultaneously. Combinable with or alternative to metformin, inositol, ALA.
-
Cardiovascular risk = post-menopausal acceleration: After 50, women’s cardiovascular risk approaches male levels. The value of a drug that targets obesity and cardiovascular risk simultaneously is substantial.
The dosing protocol is gradual escalation. 3mg → 7mg → 14mg → 25mg, increased every 4 weeks. Slow titration minimizes side effects (nausea, vomiting, diarrhea). Take 30 minutes before food on empty stomach with a full glass (120mL+) of water. No other beverages, food, or medications for 30 minutes after. Strict for absorption — but less burden than injections.
Side effect profile mirrors injectable GLP-1: nausea (20–30% early), vomiting (10–15%), constipation, diarrhea. Most adapt within 4–8 weeks. Pancreatitis history and family history of medullary thyroid cancer are contraindications. Not used in pregnancy or lactation (women planning pregnancy should discontinue at least 2 months before conception). Modest gallstone risk increase, caution with gastroparesis.
Muscle loss concerns are common to all GLP-1 drugs. About 30–40% of weight loss comes from muscle and bone according to data. Protein 1.2–1.6g/kg/day + resistance training (2–3×/week) + vitamin D + calcium constitute the necessary matrix. Bone density loss is a sharper concern in women, so calcium 1,200mg + vitamin D 1,000–2,000 IU + resistance training are emphasized.
Cost: estimated US market price $1,000–1,300/month (pre-insurance). Korean market entry expected in 12–18 months. Insurance coverage and specialty disease cost reimbursement will be set at launch. Out-of-pocket Korean pricing potentially ₩600,000–1,000,000/month.
Without lifestyle change, drug effects don’t hold. Post-discontinuation data from SELECT follow-up showed approximately two-thirds weight regain on average. Dietary pattern restructuring, exercise habits, and sleep are the matrix that locks in drug efficacy. The drug is the starting line, not the finish.